IL2 and neoplasm: The first was inflammation-related pathways, such as the IL6/JAK/STAT3 signalling, inflammatory response, IL2/STAT5 signalling, TNF-alpha signalling via NFKB, and KRAS signalling pathways, which have been proven to be associated with tumours.